WCLC 2025 - Posters & ePosters-P3.13.12 Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNEC Patients

P3.13.12 Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNEC Patients

Asset Subtitle

Graeme Fenton

Meta Tag

Speaker Graeme Fenton

Topic Small Cell Lung Cancer and Neuroendocrine Tumors